clinical trial · NCT07186946
Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants
Thryv Therapeutics, Inc.·phase1·completed·n = 16
Heart FailureTHRV-1268Placebo
brief summary
A research study that involves the use of an investigational drug called THRV-1268. The main purpose is to measure the safety (whether it causes any side effects) and tolerability (if it does cause any side effects, how well your body is able to handle them) in healthy obese adults. This study will also look at how the drug moves through the body, is absorbed, distributed, metabolized and eliminated.
started
Sep 15, 2025
primary completion
Oct 20, 2025
completion
Oct 20, 2025
last updated
Jan 14, 2026
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Comparative Bioavailability (Unblinded) of THRV-1268 in Health Obese Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol